MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 05-16-2026
DURECT Corporation Total Liabilities 2011-2026 | DRRX
Annual Total Liabilities DURECT Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 63.2 M | 30 M | 31.6 M | 32.2 M | 31.9 M | 31.6 M | 10.1 M | 9.6 M | 45.7 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 63.2 M | 9.6 M | 31.8 M |
Total Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
52.3 M | $ 5.47 | 11.18 % | $ 81.3 M |  USA |
 |
Evoke Pharma
EVOK
|
10.5 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
250 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
12.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.6 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
449 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
26.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
107 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
54.2 M | $ 2.63 | -4.01 % | $ 1.01 B |  Canada |
 |
Harrow Health
HROW
|
347 M | $ 31.21 | 1.13 % | $ 1.15 B | USA |
 |
Athenex
ATNX
|
228 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
90.4 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
6.15 B | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
367 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
173 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
10.3 B | - | - | $ 28.9 M |  Irlanda |
 |
Organogenesis Holdings
ORGO
|
165 M | $ 2.41 | -6.95 % | $ 305 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.42 | -0.55 % | $ 1.98 B | Canada |
 |
Pacira BioSciences
PCRX
|
775 M | $ 22.64 | -3.78 % | $ 1.05 B | USA |
 |
Solid Biosciences
SLDB
|
52.5 M | $ 6.92 | -9.31 % | $ 606 M | USA |
 |
Canopy Growth Corporation
CGC
|
430 M | $ 1.04 | -2.8 % | $ 112 M | Canada |
 |
Tilray
TLRY
|
977 M | $ 5.32 | -3.27 % | $ 3.29 B | Canada |
 |
Aurora Cannabis
ACB
|
244 M | $ 3.32 | -0.9 % | $ 182 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
9.28 M | $ 1.09 | -7.63 % | $ 1.35 M | USA |
 |
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
735 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
102 M | $ 1.07 | -1.83 % | $ 102 M | Canada |
 |
Evolus
EOLS
|
249 M | $ 6.5 | -1.22 % | $ 419 M | USA |
 |
Sundial Growers
SNDL
|
235 M | $ 1.43 | -2.05 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
11.5 M | $ 2.11 | 0.96 % | $ 30.9 M | USA |
 |
Emergent BioSolutions
EBS
|
1.17 B | $ 7.94 | -3.29 % | $ 407 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
23.7 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
24 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
434 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
3.19 M | $ 0.77 | -6.44 % | $ 3.1 M | USA |
 |
Assertio Holdings
ASRT
|
173 M | $ 23.32 | - | $ 149 M | USA |
 |
PetIQ
PETQ
|
478 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
7.49 M | $ 6.9 | -7.01 % | $ 272 M | USA |
 |
Recro Pharma
REPH
|
94.8 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
194 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
9.65 M | $ 0.74 | -4.0 % | $ 37 M | USA |
 |
PLx Pharma
PLXP
|
25 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
22.5 B | $ 16.48 | -4.52 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
11.6 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.29 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
20.2 M | $ 0.79 | -0.55 % | $ 28.4 M | USA |
 |
Tricida
TCDA
|
168 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
8.26 M | $ 1.04 | -16.13 % | $ 4.46 M |  China |
 |
TherapeuticsMD
TXMD
|
10.8 M | $ 2.0 | 0.5 % | $ 23.1 M | USA |